Welcome to the Institute of Clinical Research

Welcome to the Institute of Clinical Research

About Us

The Institute of Clinical Research (ICR) is the probably the oldest independent membership-led professional body for global clinical researchers.  

For over 40 years, The Institute of Clinical Research (ICR) has provided high quality training, networking and support to the clinical research community.  For many Members the Institute has been part of their life throughout their working careers, many have been with the Institute since its first incarnation as the ACRPI.

It is the membership that makes the Institute.

How does it all work ?

The Institute of Clinical Research is you, the Membership governed by the Articles of Memorandum drawn up by the founding members.

The Board is made up of members who give their time freely to guide the future direction of the ICR.

The ICR Secretariat is the administrative arm of the Institute, its primary focus is to ensure that the wishes of the Board and Membership are carried out and to see to the day to day tasks that any membership organisation generates.


Our Mission

The ICR exists to support our members through all stages of their careers. We do this, in part, by:

  • Defining and refining standards for our profession
  • Providing a forum for discussion of key issues impacting clinical research
  • Promoting good relations with other healthcare related groups 
  • Providing opportunities for learning and development to enhance professional competence 
  • Enhancing public confidence and understanding of clinical research


Current News

Novartis lung cancer drug Tabrecta gets approval

By ICR Secretariat / 30/06/2022 01:30 PM

Novartis has announced that the European Commission (EC) has approved Tabrecta – also known as capmatinib – as a monotherapy for the treatment of adul…

UCB lowers 2022 profit expectations amid Ukraine war, rising costs

By ICR Secretariat / 30/06/2022 01:29 PM

Generic competition, a complete response letter, a new acquisition and external pressures have created a perfect storm for UCB, leading the company to…

Sanofi and GSK report successful efficacy results against Omicron

By ICR Secretariat / 30/06/2022 01:28 PM

Sanofi and GSK have announced positive data from their vaccine trial which evaluated an adjuvanted Beta vaccine candidate. This included 75.1% efficac…

NICE recommends Eli Lilly’s breast cancer therapy

By ICR Secretariat / 27/06/2022 10:49 AM

Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence

Roche Alzheimer's study fails in another setback to a long-tested hypothesis

By ICR Secretariat / 27/06/2022 10:48 AM

An experimental and closely followed drug for Alzheimer’s disease has failed a key clinical study, dealing yet another blow to the prevailing theory o…

Amid death risk fears, Clovis pulls Rubraca in 3rd-line ovarian cancer as PARP player plugs away at earlier setting

By ICR Secretariat / 27/06/2022 10:36 AM

A death risk signal has taken a toll on Clovis Oncology’s already lagging ovarian cancer drug, Rubraca. The company has taken FDA's hint, withdrawing …

FDA advisers offer unanimous support to second Bluebird gene therapy

By ICR Secretariat / 21/06/2022 03:27 PM

For the second time in two days, advisers to the Food and Drug Administration gave their unanimous support to an experimental gene therapy for a rare …

Fierce Pharma Asia—Enhertu's standing ovation; Tessa's $126M CAR-T financing; Samsung's manufacturing deal

By ICR Secretariat / 21/06/2022 03:26 PM

AstraZeneca and Daiichi Sankyo's Enhertu looked on track to open a new breast cancer category: HER2-low. Singapore's Tessa Therapeutics grabbed $126 m…

GSK claims first positive Phase 3 result for an RSV vaccine

By ICR Secretariat / 21/06/2022 03:25 PM

  • GSK’s experimental vaccine for respiratory syncytial virus prevented disease in adults 60 and older, the company said Friday, clearing the way for th…

Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme

By ICR Secretariat / 15/06/2022 11:01 AM

Since their PCSK9 drugs to lower bad cholesterol won FDA approvals a month apart in the summer of 2015, Amgen and Regeneron have waged a war for supre…

Bristol Myers’ autoimmune drug shows potential in lupus

By ICR Secretariat / 15/06/2022 10:59 AM

  • Bristol Myers Squibb’s experimental autoimmune disease drug deucravacitinib helped treat moderate-to-severe lupus in a Phase 2 trial, the company rep…

Pfizer topples oncology giant Roche in cancer patient groups' reputation list

By ICR Secretariat / 15/06/2022 10:32 AM

Pfizer has become the most reputable pharma company for cancer patient groups, knocking Roche out of the top spot.

Thousands to potentially benefit from Roche treatment for sight loss

By ICR Secretariat / 06/06/2022 11:30 AM

The National Institute for Health and Care Excellence (NICE) has recommended Roche’s faricimab (Vabysmo) as a treatment option for two leading forms o…

Idorsia taps more star power, enlisting actor Taye Diggs to pitch newly launched insomnia drug Quviviq

By ICR Secretariat / 06/06/2022 11:29 AM

Count Broadway star Taye Diggs as the latest addition to sleep drug maker Idorsia’s celebrity arsenal. Just a few weeks after its insomnia drug Quvivi…

Merck study results signal blood cancer potential for new type of immunotherapy

By ICR Secretariat / 06/06/2022 11:27 AM

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Mer…

ICR Project Management Forum - Friday 30th September at IQVIA - Reading

By ICR Secretariat / 30/05/2022 02:56 PM

We are pleased to announce our annual Project Management Forum will be held on

Friday 30th September at IQVIA - Reading

Understanding Project Manageme…

GlaxoSmithKline is no more: Meet the scaled down 'GSK'

By ICR Secretariat / 25/05/2022 11:48 AM

More than two decades ago, Glaxo Wellcome and SmithKline Beecham combined to become GlaxoSmithKline. But as the British Big Pharma looks to slim down …

NHS patients missing out on new medicines that could extend lives

By ICR Secretariat / 25/05/2022 11:43 AM

Data shows that 1.2 million additional NHS patients are currently eligible for vital medicines but are missing out

Most influential people in biopharma—the entrepreneurs

By ICR Secretariat / 25/05/2022 11:20 AM

This is the third week in our Most Influential People in Biopharma series, following features on CEOs and scientists earlier this month. The last sect…

FDA rejects two China-developed cancer drugs

By ICR Secretariat / 19/05/2022 03:45 PM

The Food and Drug Administration has refused to approve two cancer treatments developed by Chinese drugmakers, citing trial design in one rejection an…

University launches hub for pregnant women with pre-existing medical conditions

By ICR Secretariat / 19/05/2022 03:44 PM

Norfolk and Norwich University Hospitals Foundation Trust opens centre to increase survival rate among pregnant women managing other conditions

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

By ICR Secretariat / 19/05/2022 03:42 PM

  • A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung …

With 200M unused doses, AstraZeneca's COVID vaccine partner Serum Institute halts production

By ICR Secretariat / 28/04/2022 02:51 PM

About 200 million doses of COVID-19 vaccine are gathering dust in warehouses of the world’s largest vaccine manufacturer as global demand ebbs.

How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials

By ICR Secretariat / 28/04/2022 02:48 PM

The outcome, no longer seen as a sure bet, could influence how future drugs for a deadly heart disease are developed.

DNA analysis uncovers new cancer treatment clues

By ICR Secretariat / 28/04/2022 02:45 PM

Researchers were able to detect specific combinations of genetic alterations which may hold key to the growth of cancers

Troubling data leads a biotech to pull its prized drug from market and FDA review

By ICR Secretariat / 21/04/2022 02:59 PM

  • The New York-based biotechnology company TG Therapeutics has decided to pull its only approved medicine from the market, after recent clinical trial …

ISA Pharmaceuticals announce new trial testing technology for cancers

By ICR Secretariat / 21/04/2022 02:57 PM

Trial of Amplivant will begin in a number of cancer patients including those with ovarian cancer

Inflation is forcing prioritization of healthcare spending — are you ready?

By ICR Secretariat / 21/04/2022 02:51 PM

If you're a pharmaceutical marketer, you're about to face a challenge no US-based marketer has seen since the early 1990s: inflation.

UK patients granted early access for radioligand therapy in advanced prostate cancer

By ICR Secretariat / 14/04/2022 12:32 PM

Advanced Accelerator Applications (AAA), a Novartis company, has announced that eligible patients in the UK have been granted early access for radioli…

Course Postponements Due to Covid

By ICR Secretariat / 10/02/2022 03:38 PM

All of our delegates and members who had course places postponed over the last two years due to covid restrictions/illness have now been contacted dir…

Events and Courses

GCP for Experts L10

This course provides an in-depth look at the regulatory systems currently in operation in the EU and their impact, together with UK legislation, ...

Foundation in Good Clinical Practice (GCP) L13

This course provides an in-depth look at the regulatory systems currently in operation in the EU and their impact, together with UK legislation, ...

Introduction To Clinical Trials & Clinical Trials Practice L20

An Introduction to Clinical Trials and Clinical Trial Practice, the ICR’s flagship training course, is accredited by Cranfield University. This h...

Clinical Investigations for Medical Devices - Foundation L21

In this one day course we explore clinical investigations for medical devices.  We will review the latest legislation and its impact on determini...

Process Thinking in Clinical Trials L22

ICH E6 (R2) has emphasized the importance of risk management in relation to ensuring subject safety and rights as well as data integrity in clinica...

Advanced Monitoring L29

In this highly practical course we look at the root cause of typical inspection findings and work with delegates to develop personal corrective a...

Current Jobs